



HAL
open science

New Molecular Diagnosis Approaches - From the Identification of Mutations to their Characterization

Anne Bergougnoux, Magali Taulan-Cadars, Mireille Claustres, Caroline Raynal

► **To cite this version:**

Anne Bergougnoux, Magali Taulan-Cadars, Mireille Claustres, Caroline Raynal. New Molecular Diagnosis Approaches - From the Identification of Mutations to their Characterization. Cystic Fibrosis in the Light of New Research, InTech, 2015, 10.5772/60679 . hal-02434957

HAL Id: hal-02434957

<https://hal.umontpellier.fr/hal-02434957>

Submitted on 4 Feb 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution| 4.0 International License

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

4,500

Open access books available

119,000

International authors and editors

135M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



New Molecular Diagnosis Approaches — From the Identification of Mutations to their Characterization

Anne Bergougoux, Magali Taulan-Cadars,
Mireille Claustres and Caroline Raynal

Additional information is available at the end of the chapter

<http://dx.doi.org/10.5772/60679>

Abstract

Molecular diagnosis of cystic fibrosis is based on the detection of mutation in the *CFTR* gene, identified in 1989. During the past 20 years, thanks to evolutions of diagnostic techniques, our knowledge of mutation spectrum and pathophysiological mechanisms involved in the disease has significantly improved. Sanger sequencing and quantitative methods greatly contributed to the identification of the 2,000 sequence variations reported worldwide in *CFTR*. We are now entering the new technological age with the generalisation of Next Generation Sequencing (NGS) technologies in diagnostics laboratories. These high throughput approaches allow scanning for the entire *CFTR* locus, including deep intronic regions, and in parallel other candidate genes that possibly influence the clinical evolution of patients. However, this powerful technology poses new challenge in test interpretation. In this chapter, we review the current and new technologies used in molecular diagnostics of cystic fibrosis, particularly NGS approaches. We also present current and new bioinformatics tools available for the interpretation of variants and *in vitro/ex vivo* and *in vivo* techniques that can be used to improve the characterization of the functional impact of *CFTR* variations.

Keywords: Next generation sequencing, *CFTR*, sequence variations, interpretation, functional characterization

1. Introduction

The autosomal recessive mode of inheritance of Cystic Fibrosis (CF) was suggested by Andersen and Hodges in 1945 when they described this disease as a pathological entity.

Since the discovery of the *CFTR* gene (and the predicted protein cystic fibrosis transmembrane conductance regulator) in 1989 [1], close to 2,000 variations have been identified on this locus. *CFTR* gene studies represent one of the most frequent genetic analyses routinely performed worldwide, either to confirm the clinical diagnosis of CF or *CFTR*-related disorders (*CFTR*-RDs), or to offer carrier testing, prenatal or pre-implantation genetic diagnosis.

The most common severe mutation, p.Phe508del, is found in approximately 70% of CF alleles of European descent (therefore it is present in 49% of homozygous and 42% of compound heterozygous CF patients), with significant variations depending on ethnicities [2]. There is a clear decreasing northwest to southwest gradient in p.Phe508del frequency across Europe. Only four other mutations represent more than 1% of CF cases: p.Gly542*, p.Gly551Asp, p.Asn1303Lys, and p.Trp1282*. All other mutations are rare and many are private, only detected within a single family.




Figure 1. Two models for the classification of *CFTR* variants: (1) Functional: five classes of defective *CFTR* protein [3, 4, 5]; and (2) Clinical: four classes based on phenotypic expression in patients [6].

Therefore, a good knowledge of CFTR diseases and their molecular pathology is required when choosing tools and strategy and when interpreting results. Organization of regional or national networks of specialist clinical and molecular genetic laboratories is needed. Two models for the classification of sequence alterations have been proposed (Figure 1): (1) depending on their molecular impact on the CFTR chloride channel, which requires *in vitro/in vivo* functional assays, now less used due to the difficulty in accurately classifying the new reported variants [3, 4] or (2) by their clinical consequences on patients based on detailed and prospective clinical evaluation of patients associated with molecular findings [5].

However, even if the most severe mutations were studied *in vitro*, mild mutations or variants of unknown (clinical) significance (VUCs or VUS) were barely analysed. Thus, only one third of CFTR variations are functionally classified. Finally, in CF, as in other genetic diseases, new molecular diagnosis techniques such as Next Generation Sequencing (NGS) allow the analysis of the whole CFTR locus (including deep intronic regions) but increase the number of VUCS reported on patients.

Therefore, geneticists and clinicians have to combine CFTR epidemiological databases, functional *in vitro/in vivo* analysis and exhaustive clinical data to perform pertinent genotype/phenotype correlations in patients in order to provide appropriate genetic counselling to families.

2. Technical aspects of molecular diagnosis

The CFTR genetic testing strategy depends on the clinical and familial context and is classically performed step by step, as recommended [7]. As shown in Figure 2, tests are carried out in various situations, including confirmation of a clinical diagnosis, prenatal diagnosis (familial context or foetal suspicion of CF) and carrier screening.

A wide range of techniques is still used to identify CFTR gene sequence variations (presented in Table 1) and there is no gold standard or preferred method for routine testing. However, laboratories should be aware of the limitations of their chosen method (e.g. some mutations are not identified). Moreover, assay performance should always be verified before diagnostic use, even though commercial kits are CE-marked *in vitro* diagnostic devices (IVDD). In the perspective of accreditation (expected in France in 2020 for hospital diagnostic laboratories), all methods used in molecular biology should be validated before diagnostic use, notably by comparison with a reference method (Sanger sequencing for Single Nucleotide Variations and quantitative PCR for Copy Number Variations detection). This technical validation should be undertaken for NGS in the step 1 and 2 diagnosis.

Undetected CFTR mutations may lie within the introns or regulatory regions, which are not routinely explored but that will be soon analysed by NGS. Comparison between NGS and reference methods for the identification of CFTR variants on these unexplored regions will be a challenge.




Figure 2. CF molecular diagnosis: a step-by-step strategy (modified from [7]). NBS: newborn screening; SNV: Single Nucleotide Variation; CNV: Copy Number Variation; MLPA: Multiplex Ligation-dependent Probe Amplification.

2.1. Current techniques to detect *CFTR* variants

2.1.1. Screening techniques (Step 1)

These approaches consist of genotyping a panel of frequent CF mutations using commercial kits (Table 1) that classically cover more than 80% of CF known mutations in European populations. Additional search for mutations specific to certain regions or ethnicities (frequency higher than 1% of CF alleles in the targeted population) completes the analyses.

Data on disease and carrier frequencies or mutation frequencies in various populations are available in the WHO report [8] and should be accurately known and used by laboratories.

For many patients carrying CF-causing mutations included in commercial panels, *CFTR* molecular analysis generally stops at this step. There is no need for additional studies, except the confirmation of mutations by a second method, as recommended by international guidelines for genetics diagnosis.

2.1.2. Scanning techniques (Step 2)

The high heterogeneity of *CFTR* mutations in CF and *CFTR*-RD populations makes the complete molecular screening of the 27 exons and parts of the regulatory regions (5'UTR, 3'UTR and partial intronic regions) essential.

Therefore, the analysis of the *CFTR* locus can be performed as follows:

- To detect SNV: scanning the 27 exons of the *CFTR* gene, intronic boundaries and four intronic regions with reported deep intronic mutations [9-12] and a part of the promoter. As an example, one can use Sanger sequencing with Single Condition Amplification Primers (SCAP) technique [13].
- To detect CNV (large *CFTR* rearrangements): scanning of exon by multiplex fluorescent quantitative PCR (Multiplex Ligation-dependent Probe Amplification or MLPA) or array-CGH [14].

These robust methods allow the detection of more than 97% of *CFTR* mutations involved in CF.

2.1.3. Advantages and limits

Classical screening or scanning methods used to detect mutations (in step 1 and 2) have high specificity and sensitivity (Table 1). Older techniques such as RFLP (restriction fragment length polymorphism), DGGE (denaturing gradient gel electrophoresis) or DHPLC (denaturing high performance liquid chromatography) were widely used in the past 20 years but were difficult to set up and showed inconstant performance. They have been progressively replaced by easy-to-use commercial kits, more appropriate for larger sample series. These kits allow PCR multiplexing and thus enable the detection of the most common CF mutations in one reaction. Sanger sequencing and quantitative PCR are the most effective to identify unknown mutations. However, all these classical methods are labour-intensive and time-consuming.

Method name	Mutations detected	Advantages	Limits
Screening (step 1)			
Reverse dot blot hybridization	Up to 20 mutations per multiplex		Partial hybridization if SNP on probe
ARMS (amplification refractory mutation system)	Up to 50 mutations	Appropriate for large series High specificity	Primer Design difficult Need of high agarose gel quality
OLA (Oligonucleotide ligation assay)	32 mutations (Abbott kit)	Cost effective	Partial hybridization if SNP on probe
NGS	139 to 166 CFTR variants		Need of sufficient coverage In development (Illumina)
Scanning (Step 2)			
HRM (High Resolution Melting curve analysis)	Heterozygous variants	Appropriate for large series (e.g. epidemiological studies)	Exon by exon Need of positive cases Not adapted for homozygous variants
Sanger Sequencing	All sequenced bases	Close to 100% sensitivity	Expensive method Can not detect CNV
Quantitative fluorescent multiplex PCR	Deletions, duplications, insertions	Simple and rapid	False positive if SNP on probe Performance dependent on DNA quality
NGS (used for step 3)	All sequenced bases	Appropriate for large series Cost effective	Need of sufficient coverage In development (Illumina)

Table 1. Overview, advantages and limits of screening and scanning techniques used in molecular genetics diagnosis (adapted from [7])

2.2. Next Generation Sequencing (NGS)

2.2.1. Principle of NGS technologies

The development of Next Generation Sequencing (NGS) or Massively Parallel Sequencing (MPS) technologies with an immense capacity (up to 1 Terabase (Tb) of data per run with the HiSeq2500 system, Illumina) is a major technical progress in the field of human genetics. Since 2004, three principal NGS platforms have been commercially available, including (i) 454 GS FLX & GS junior from Roche (ii) Genome Analyzer, HiSeq & MiSeq from Illumina and (iii) SOLiD & Ion Torrent PGM from Life Technologies-Applied Biosystems (AB) [15]. These technologies differ in terms of sample library preparation workflow, enabling sequencing on any of the current NGS sequencers (e.g. Illumina, Life technologies, Roche). Since late 2004, three principal NGS firms developed sequencers commercially available (listed in Table 2).

454 pyrosequencing is a sequencing-by-synthesis method that measures the release of inorganic pyrophosphate upon incorporation of nucleotides, by converting it into luciferase chemiluminescent signals using a series of enzymatic reactions. Ion Torrent semiconductor technology is also based on a sequencing-by-synthesis approach but measures pH changes (instead of light) induced by the release of hydrogen ions as nucleotides are incorporated. SOLiD technology is a ligation-based sequencing system. DNA ligase is used to identify the nucleotide present at a given position in a DNA sequence; each base is read twice, which increases accuracy, even for homopolymeric regions. Base detection uses a mixture of labelled oligonucleotides, which queries the input strand with ligase. In Illumina system, clonal amplification is performed using a process termed 'bridge amplification' followed by two basic steps, initial priming and extending of the single-stranded, single-molecule template and bridge amplification of the immobilized template with immediately adjacent primers to form clusters. For sequencing, only dye-labelled terminators are added; then the sequence at that position is determined for all clusters; next, the dye is cleaved and another round of dye-labelled terminators is added.

Platform	GAII, HiSeq & MiSeq	Ion Torrent	SOLiD	GS FLX & GS Junior
Methodology	Sequencing by synthesis (Reversible termination)	Sequencing by synthesis	Sequencing by Ligation	Sequencing by synthesis (Pyrosequencing)
Loading	Adaptors on template DNA bind high density primers across surface of slide	Adaptors on template DNA bind primers on beads, one molecule per bead	Adaptors on template DNA bind primers on beads, one molecule per bead	Adaptors on template DNA bind primers on beads, one molecule per bead
Clonal amplification	Bridge PCR: Surface array on flow cell	Emulsion PCR: clusters on beads	Emulsion PCR: clusters on beads	Emulsion PCR: clusters on beads
Parallelisation	Random array on flow cell	Beads loaded on a chip	Beads bonded to high density glass slide	Beads loaded onto high density plate
Detection	Fluorescence	H ⁺ ions (sensitive pH meter)	Fluorescence	Light (luciferase)

Table 2. Overview of the main NGS technologies

2.2.1.1. Target enrichment

Targeted re-sequencing isolates genomic regions of interest in a sample library, allowing to focus efficiently and cost-effectively on a small subset of the genome, such as an exome, a particular chromosome, a set of genes or a region of interest such as a whole gene. Two main strategies can be envisioned: capture [16, 17] or amplification relevant genomic DNA [18-20] as shown in Table 3.

Strategy	Capture/hybridisation-based method			Amplicon-based method		
Methods	HaloPlex	SureSelect (Agilent) /SeqCap Nextera (Illumina) (NimbleGen)		Microdroplet (RainDance Technologies)	Multiplex PCR (AmpliSeq, Life Technology & TrueSeq, Illumina)	Long-Range PCR Qiagen & "home" design
Main steps	Restriction enzyme digestion	Sonication/ nebulisation	Tagmentation with transposon	Sonication	PCR amplification	PCR amplification
	Probe hybridisation	PCR amplification + probe hybridisation	PCR amplification + probe hybridisation			Sonication/ nebulisation
						Ligation of sequencing adaptors

Table 3. Main strategies proposed for target enrichment

2.2.1.2. Advantages and limits

The main advantages of the technology are related to its capability to process a large number of samples in parallel. NGS technologies are time saving and lower the costs per patient, of step 1 and particularly step 2 molecular analyses. But, they also have significant limitations such as high error rates, enrichment of rare variants and large proportion of missing values, as well as the fact that most current analytical methods are designed for population-based association studies. With second generation sequencing, it is necessary to clonally amplify the isolated targets in order to generate sufficient signal for detection during the sequencing run generating clusters of many thousands of identical DNA targets. In addition, each NGS platform generates different read lengths that range from short (e.g. 35 bases) to long reads (over 500 bases). For a number of applications, including targeted re-sequencing, ChIP-Seq and RNA-Seq, short reads are highly informative and adequate. Conversely, longer reads are more suitable for *de novo* genome assembly, mapping of high homology regions (related gene family and pseudogenes) and sequencing of repetitive DNA regions, such as introns. This is an important consideration since short read length can make accurate assembly and alignment computationally challenging.

For some clinical applications, as NGS produces massive amounts of data, their analysis and interpretation are time-consuming, not trivial and a real challenge even if specific portions of a genome is analysed.

2.2.1.3. Bioinformatics software to analyse NGS data

Then, generated data are analysed by bioinformatics tools. Quality criteria such as confidence or coverage are guarantees for optimal sensitivity and specificity of a sequencing run. Bioinformatics analyses are frequently performed by using software developed by sequencers' companies. The three steps include (1) base calling and quality score computation, (2) assembly and alignment and (3) variant calling and annotation. Laboratories developed their own 'in-house' pipeline mainly to apply filters allowing an easy focus on causing-mutations. Others use free web resources to realign files including BWA (<http://bio-bwa.sourceforge.net>) or to perform a new variant calling such as Samtools and GATK [21-23]. Others serve as Viewer such as Integrative Genomics Viewer (<http://www.broadinstitute.org/igv/>). Galaxy website is an integrative platform offering the possibility to view and process files generated by NGS. Many databases, useful for variant annotation and sometimes inserted in others programs or pipelines, are publicly available including the 1000 Genomes Project [24] and the dbSNP database [25] (further described in part 3.1.1).

Many tracks are currently studied (i.e. improvement of bioinformatics tools, comparison of NGS approaches between CF laboratories, development of databases including newly detected NGS variants, publication of guidelines and definition of a diagnosis report model) to make CF molecular diagnosis by NGS suitable for different clinical and familial cases.

2.2.2. Indications and choice of CFTR analysed regions

In the case of Mendelian diseases caused by mutations in a single gene, like *CFTR* in Cystic Fibrosis, NGS sequencing of entire genome or exome is still useless and expensive. Collaborations between companies specialized in molecular diagnosis and academic laboratories recently led to the establishment of new molecular diagnosis tools based on NGS. Combination of (i) the enrichment of regions of interest by hybrid capture, circularization or Polymerase Chain Reaction (PCR) and (ii) high throughput sequencing now allows time-efficient and economical way to perform analyses. Use of NGS technology as a first intention is currently set up in laboratories, which will soon question the CF diagnosis strategy as a tree. As shown in Figure 2, in our actual CF molecular diagnosis strategy, NGS technology can be used instead of 'classical' techniques for the detection of a panel of common mutations (step 1) or to analyse the '*CFTR* exome' (step 2). Technical manipulations are similar for both, but filters can be used to focus on regions that contain mutations. Multiplicom® and Illumina® propose a locus specific design to library preparation for molecular analysis of the '*CFTR* exome'. CE-marked kits for *in vitro* diagnostic (CE-IVD) and efficient bioinformatics tools are commercialized. The latter could be performed by in-house pipelines or subcontract on commercial firms (Sophia Genetics®). SNV and indels are correctly detected (high specificity and sensitivity) and CNV detection is now available for some amplicon-based methods.

Furthermore, in patients with definite CF clinical diagnosis (positive sweat test, CF clinical features) and who carry no or only one CF mutation, step 3 analysis could be ultimately proposed, in combination with the analysis of potential modifiers genes (see next section)

In literature, three studies reported NGS *CFTR* sequencing (Table 4) on CF patients, CF carriers or controls samples [18, 26, 27]. Abou Tayoun and colleagues [26] first proposed a proof-of-

concept for a ‘CFTR exome’ analysis by NGS on 79 samples. Target enrichment was performed by PCR amplification (AmpliSeq Panel, Life technologies) and Sequencing on Ion Torrent Platform (PGM®). Their sequencing offered minimal coverage of 100X (depending on the Ion 314 or 318 chip used). Two others studies realized sequencing of the whole CFTR locus (close to 250 kb) including deep intronic CFTR regions (Figure 2, Step 3). Trujillano *et al.* [27] reported the CFTR re-sequencing by hybridization capture on a custom NimbleGen SeqCap EZ Choise array using HiSeq2000 (Illumina®) in a set of 92 samples. They highlighted the precise characterization of breakpoints of seven genomic rearrangements in CFTR.

We proposed a complete CFTR gene sequencing of DNA samples from patients with a confirmed CF clinical diagnosis but with an incomplete genotype [18]. Although large unexplored intronic regions might contain few mutations (about 1%–3% of CF mutations), we identified a new pathogenic mutation, which creates a pseudo-exon (Table 4). Moreover, we compared hybridization capture and Long-Range PCR to target enrichment and used a small-scale NGS platform for sequencing (GS Junior Sequencer, 454 Life Sciences®). Some promising variants were then confirmed as deleterious by *in vitro/ex vivo* functional assays. However, for most detected intronic variants, classification will be a long and difficult way. This approach is currently under development for CF diagnosis.

	Abou Tayoun et al., 2013 [25]	Trujillano et al., 2014 [26]	Bonini et al., 2015 [17]	
Samples	57 subjects already genotyped – 22 cell lines: 24 CF, 46 CF carriers, 9 controls	92 subjects already genotyped: 45 CF, 27 CF carriers, 20 CFTR-RD	18 CF subjects in whom only one mutation had identified	
Study objectif	Proof of concept of CFTR assay by NGS	Resequencing mutations Validation technique	Identification of the second mutation Comparison of two target enrichment approaches	
Sequencing protocol				
Regions analyzed	All CFTR exons and 20bp of all intron/splice sites (10 343bp)	All CFTR locus (208kb – 181kb after masking repetitive DNA elements)	All CFTR locus (250kb) 2.1million probes (60-90pb)	36 overlapping fragments (7.3-14.5kb)
Target enrichment	Custom AmpliSeq panel (Life technologies)	Hybrid capture: Custom NimbleGen SeqCap EZ	Hybrid capture: Custom NimbleGen SeqCap EZ	Long-Range -PCR (LR-PCR) enrichment
Initial DNA quantity per sample	20ng		500ng	750ng
Library preparation	2 separate primer pools (2x36 amplicons), end-repair, ligation to adaptators, quantification of Library pooled bar-coded libraries Clonal PCR	Sonication (Covaris) End-repair, A-tailing, ligation to index adaptators (TrueSeq protocol) CR), PCR amplification, quantification of Library (bioanalyzer), in-solution hybridization	Nebulization; End-repair, ligation to adaptators, quantification of Library, Clonal emulsion PCR	Nebulization; LR-PCREnd-repair, phosphorylation, ligation to MID adaptators, quantification of Library, Clonal emulsion PCR
Sample Multiplexing and cost	5 to 35 samples	8 to 24 samples	No multiplexing	4 samples
NGS technology	200bp single reads Ion 314TM (10Mb) or Ion 318 (1Gb) Ion torrent Personal Genome Machine (PGM)	2x100bp paired-end reads HiSeq 2000 instrument (Illumina)	Single or Paired-end reads, up to 450 bp GS Junior Sequencer (454 Life Sciences)	

	Abou Tayoun et al., 2013 [25]	Trujillano et al., 2014 [26]	Bonini et al., 2015 [17]
Mapping	Human genome	Human genome (GATK pipeline and picard-tools)	Human Genome (454 Roche GS Junior data analysis pipeline)
Minimal coverage		Mean: 231X 99,7% covered by minimum 5 reads	40X
CFTR Sequencing statistics			
Specificity	97% (22 on 23 mutations)	100%	ND
Sensitivity	100% (23 on 23 mutations)	100% (122 on 122 variants)	ND
Reproducibility	100% (56 on 56 variants in 3 independent runs)	100% (8 on 8 variants)	ND
Bioinformatics tools			
CNV	Depth-Of-Coverage tool from the Genome Analysis ToolKit (GATK) --> Log2 ratios < -0.7: deletion	Pindel; Conifer; PeSV-Fisher 5 large deletions, 1 duplication and 1 genomic rearrangement	ND
SNV	7 variants per sample on average	115 SNV + 28 InDels on average per sample	197 variants on average per sample (118 in introns)
Variant identification and calling	Not notified	Variant prediction tools: GATK Unified Genotyper, samtools mpileup, SHORE	Reference Mapper Mutalyzer SeqNext (JSI medical systems)
Variant filter	Min coverage: 20 reads Threshold: 25% reads Both strands	GATK Variant filtration (MQ<30.0; QUAL<25.0; QD<4.0; DP<5; DP<2000; GQ<15) GATK Combine Variant	Threshold 30% of reads Heterozygous: Read support: 30-65% Homozygous >70%
Databases	Variant frequency > 1% dbSNP Exome Variant Server CFMDB CFTR2	1000 Genomes project dbSNP Exome Variant Server CFMDB CFTR2	1000 Genomes project dbSNP
<i>In silico</i> analysis	SIFT Mutation Taster	Annovar SIFT, PolyPhen2, PhyloP, Mutation Taster, phastCons UCSC Genome Browser	Annovar, HSF, MaxEnt, NNSplice, SIFT, Polyphen2, PhyloP, UCSC Genome Browser, Ensembl, MutationTaster
Performance			
Diagnostic rate	ND	98.91%	88.9% (16 / 18)
Particular cases	False positive c.2052del (2184delA) Sanger sequencing to determine the c. 1210-34TG(11-13)T(5-9) haplotype	In-house script to determine the c. 1210-34TG(11-13)T(5-9) haplotype	False positive c.2052del (2184delA) Sanger sequencing to determine the c. 1210-34TG(11-13);-12T(5-9) haplotype
Advantages	Robust, specific, limited number of VUCs	Breakpoints of large genomic rearrangement accurately determined	LR-PCR more adapted for complete gene resequencing New intronic mutations identified
Limits	SINE/LINE repeats (amplification and mapping) Homopolymer stretches (Sequencing)	GC rich genomic segments (target enrichment) Errors in index tags (sequencing)	SINE/LINE repeats (amplification and mapping) Homopolymer stretches (Sequencing) Uncaptured region in intron 3

Table 4. Comparison of three NGS strategies for *CFTR* sequencing

2.3. Other loci

With the perspectives of high throughput molecular diagnosis in genetics laboratories, CF, CFTR-RDs and CF-like diseases could be simultaneously explored in patients using NGS. Various gene panels could be investigated according to patients' phenotypes. Therefore, NGS approaches could contribute to (i) identify and confirm the implication of modifiers genes and (ii) improve molecular diagnosis of atypical Cystic Fibrosis, CFTR-RDs or CF-like diseases. Several sequence changes located in the so-called 'modifier genes' have been associated with progression of lung disease in CF patients. A decrease of pulmonary function measured by FEV1 (the forced expired volume after 1 s of blowing out) was associated with SNVs in *EDNRA*, *ACER*, *IFRD1*, *IL8*, *MUC5AC* and *TGF- β 1* genes. Haplotype 8.1 and variants in *MBL2* gene were related to *Pseudomonas aeruginosa* colonization [28, 29]. SNVs in *SNAP23*, *PPP2R4*, *PPP2R1A* and *KRT19* were recently associated with a decrease of lung function. Interactions between CFTR and these altered proteins may modify CFTR trafficking and membrane stability and therefore modify phenotype of CF patients [30]. Moreover, changes in other modifier genes were suspected to have an effect on intestinal obstruction (*DCTN4*, *ADIPOR2* and *MSRA* genes), CF-associated diabetes (*TCF7L2* gene) or liver disease (*SERPIN1A1*) [31].

CFTR-Related disorders comprise congenital bilateral absence of vas deferens (CBAVD), pancreatitis, diffuse bronchiectasis and nasal polyposis. Classically, two *CFTR* mutations (a severe and a mild mutation or two mild mutations) are found in well-characterized CBAVD patients [32]. In addition, Sharma *et al.* reported 2 SNVs on *TGF- β 1* and *ENDRA* genes associated with urogenital anomalies [33]. Chronic pancreatitis is caused by *CFTR* variations in some cases, and mutations in *CTRC*, *PRSS1*, *PRSS2* or *SPINK1* are also involved and must be analysed.

The implication of *CFTR* in diffuse bronchiectasis or nasal polyposis is more controversial [34]; variants in other genes were previously reported as possibly causative. However, the identification of mutations in other genes with sufficient significance remains difficult and needs large patient cohorts. In fact, in airway tract diseases, the influence of environment (pollutants, drugs/therapy and way of life) complicated the achievement of unbiased studies. Nevertheless, the hypothesis of oligogenism is supported by a study that reported mutations in ENaC channel genes (*SCNN1A*, *SCNN1B*, *SCNN1G*) or *SERPIN1A1* in CF-like patients (borderline sweat-test and suggestive CF clinical features without two *CFTR* mutations) [35].

Finally, a pleiotropic effect of *SLC26A9* on meconium ileus, pancreatic damage and lung disease has been identified [36], as well as *SLC9A3* for meconium ileus and lung disease and *SLC6A14* for meconium ileus and both lung disease and age at first *P. aeruginosa* infection [37]. Thus, the existence of pleiotropic effect of modifier genes on CF evolution may encourage the development of new therapeutic targets with multi-organ benefits.

3. Functional characterization of *CFTR* sequence variations

To provide appropriate diagnosis and prognosis to CF patients and also appropriate genetic counselling to families, the impact of variants identified by the techniques detailed above has to be functionally characterized.

Some variants such as frequent mutations (found in more than 1% of CF mutated alleles), nonsense or frameshift mutations are readily classified as pathogenic mutations. However, the frequent identification of rare sequence alterations of unknown pathogenicity (VUCS, VUS) substantially complicates test interpretation. Moreover, their number will increase with the diffusion of NGS technologies. To facilitate classification of these variants, CF laboratories have to combine several tools like central mutation databases or *CFTR* locus specific databases, *in silico* prediction tools and *ex vivo/in vivo* functional analyses [38, 39].

3.1. Epidemiological data and locus specific databases dedicated to *CFTR*

3.1.1. Core or central mutation databases

Their goal is to collect all sequence variations detected in all genes and to describe each mutation briefly. These databases are used to assess the frequency of a variation (minor allele frequency (MAF) lower or higher than 1%) in the general population (i.e. unaffected individuals). Since a MAF higher than 1% reflects a low probability for the variant to be pathogenic, such data may be highly informative for the interpretation of variants.

3.1.1.1. The National Center for Biotechnology Information (NCBI) short genetic variations database dbSNP

dbSNP [25] is the most comprehensive directory of single nucleotide variations. It catalogues short variations in nucleotide sequences from a wide range of organisms. Genetic Variations may be common, thus representing true polymorphisms, or they may be rare. Some of these rare human entries have additional information associated with them, including disease associations, genotype information and allele origin, as some variations are somatic rather than germ-line events. Genotypes and allele frequencies information for various populations from different studies, including data from the HapMap project, are also available.

3.1.1.2. Databases specifically collecting data from NGS projects

1000Genomes [24] aimed to find most genetic variants that have frequencies of at least 1% in samples from five populations: East Asian, South Asian, African, European and American ancestries. As in dbSNP, genotypes and allele frequencies information are available for a large number of variants [40].

Exome Variant Server [41] is a database that collects data of the NHLBI GO Exome Sequencing Project (ESP). This project aimed to discover novel genes and mechanisms contributing to various disorders by sequencing the protein coding regions of the human genome (i.e. exome) using NGS technology. As the *CFTR* gene is widely studied, this tool would not be of added value compared to dbSNP and 1000 Genomes.

3.1.2. Locus Specific Databases (LSDBs) dedicated to *CFTR*

LSDBs are now recognized as the best mode of collecting and curating lists of mutations related to human genetic diseases [42]. They compile in a single bioinformatics tool disease-causing

and non-disease-causing sequence variations identified by genetics laboratories in families with a history of a given Mendelian disease. The most sophisticated ones integrate clinical and biological data, information on the geographic and/or ethnic origin, frequency of variations in the general population, mutation hot spots and all useful information for diagnosis, prognosis and the evaluation of genotype/phenotype relationships [43].

Here we choose to detail three LSDB dedicated to *CFTR* that provide complementary information for the interpretation and the characterization of variants identified in diagnostics practice.

3.1.2.1. *Cystic fibrosis mutation database*

The Cystic Fibrosis Mutation Database (CFMDB) [44] also called 'CFTR1' is an open access database dedicated to the collection of sequence variations in the *CFTR* gene for the international CF genetics research community. It was initiated by the Cystic Fibrosis Genetic Analysis Consortium (CFGAC) in 1989 and is maintained by the Cystic Fibrosis Centre at the Hospital for Sick Children in Toronto. CFMDB allows the direct submission of new variants by laboratories, by filling out an on-line standardized form with the possibility to detail phenotypic data, genotype (i.e. other variants identified in patient) or epidemiological data. The key point of this database is to collect the largest number of *CFTR* sequence variations identified in patients, relatives and partners. On the other side, because the submission procedure applies only to the initial report of each variant, CFMDB does not provide frequency data, available with the two other databases described below. Finally, contributors do not always follow HGVS recommendations and a same variant can be reported by several laboratories under different names, possibly leading to misinterpretation or misreporting in diagnosis reports.

3.1.2.2. *Clinical and functional translation of CFTR database CFTR2*

CFTR2 [45] is a website designed to provide information about specific CF mutations to patients, researchers and the general public. For each mutation included in the database, it provides information about whether a given mutation causes cystic fibrosis when combined with another CF-causing mutation and clinical and biological information (sweat chloride, lung function, pancreatic status and pseudomonas infection rates) in patients carrying the mutation. A specific section for health practitioners and scientists provides more in-depth and research-related information.

The goal of the CFTR2 project is to categorize all mutations seen in CF patients as disease-causing (always resulting in CF when combined with another CF-causing mutation), neutral or mutation of varying clinical consequences (CF and CFTR-RD). Mutations that have not been fully analysed are considered of unknown clinical significance.

The major advantages of CFTR2 are (i) the collection of detailed clinical characteristics on large cohorts of individuals [46] that provide useful information related to a given genotype, and (ii) results of functional testing that are key arguments for their final interpretation [47].

However, this database only collects clinical and genetic data of CF patients (from national registers) that can lead to a bias of phenotypic spectrum assessment of several mutations

considered as CF-causing mutations while they were also reported in CFTR-RD patients in *trans* of other CF-causing mutations.

3.1.2.3. The French molecular database CFTR-France

CFTR-France [48] has been developed since 2012 with the aim to collect, store and process any category of variants identified in the *CFTR* gene, thanks to the collaboration of nine French laboratories with high expertise in the molecular analyses of this gene. Its specificity is to compile and annotate any category of variations (disease-causing, non-disease-causing and variants of unknown clinical significance) that have been identified by collaborators in patients affected with CF or CFTR-RD, in foetuses with abnormal ultrasonography (e.g. echogenic bowel), newborns with pending or inconclusive diagnosis and asymptomatic individuals carrying at least one sequence variation on each *CFTR* gene (i.e. carrying two variations in *trans*). The database includes the main clinical data of these individuals, genetic information from familial segregation studies and various variant annotations (frequency in patients and controls populations, sequence homology, predicted or experimentally assessed functional impact, etc.), allowing the analysis of genotype/phenotype relationships.

Thus, *CFTR*-France, by collecting all phenotypes, reflects the phenotypic spectrum of a large number of mutations. It also reports mutations in complex alleles with association frequencies (related to all individuals recorded in the database), and gives the up-to-date HGVS nomenclature of mutations.

Data collected in *CFTR*-France are provided by level 2 (specialised) and reference laboratories, so that patients analysed only by level 1 laboratories (searching for the most common mutations) are not included in the database.

Note: Access to *CFTR*-France is currently restricted to collaborators. A public access program is in progress for the medical and scientific community and for patients and families.

3.2. *In silico* prediction analyses

3.2.1. Variants located in exons and exon-intron boundaries

3.2.1.1. Prediction tools for the assessment of the impact on protein

Prediction methods of amino acid substitutions use protein sequence, structure and/or annotation. Disease-causing mutations that affect protein function tend to occur at evolutionarily conserved sites and/or at key positions in protein structure. Multiple sequence alignment of orthologous sequences reveal what positions have been conserved through evolution, and these positions are supposed to be important for protein function. Annotation can enhance prediction for variants located in structurally and functionally important domains, but this information is often sparse.

The issue of the efficiency of prediction tools in assessing possible pathogenicity of missense variants in the *CFTR* gene is of major interest, since they constitute the vast majority of VUS

identified in patients. Diagnostics laboratories frequently use those tools and particularly in problematic situations. Unfortunately their performance has not been clearly established and results (i.e. score of pathogenicity) may be discordant for a given variant.

Predictions of the impact of non-synonymous substitutions in CFTR are mainly based on multiple sequence alignment of orthologous sequences. Indeed, even if a partial 3D model of the CFTR protein has been established [49, 50], prediction tools do not take into account these elements in the final ‘score of pathogenicity’. It is classically recommended to use several prediction tools to obtain concordant predictions that could be considered for variant interpretation.

Table 5 summarizes bioinformatics programs classically used by diagnostics laboratories [51-53] and the new software SuSPect [54].

Method and Web site	Algorithm	Output
PolyPhen 2 [54]	Sequence conservation, structure to model position of amino acid substitution, and SWISS-PROT annotation	Score ranges from 0 to a positive number, where 0 is neutral, and a high positive number is damaging
SIFT [55]	Sequence homology: scores are calculated using position-specific scoring matrices with Dirichlet priors	Score ranges from 0 to 1, where 0 is damaging and 1 is neutral
Align GVGD [56]	Multiple sequence alignments to characterise the biochemical properties (composition, polarity and volume) of the observed amino acids at each position	The prediction classes form a spectrum (C0, C15, C25, C35, C45, C55, C65) with C65 most likely to interfere with function and C0 least likely.
SuSPect [57]	Sequence-, structure*- and systems biology-based features to predict the phenotypic effects of missense mutations. Algorithm trained using VariBench (contains information for experimentally verified effects) <i>*Structure-based comparison with other ABC transporters</i>	Table of scores from 0-100, colour-coded according to predicted deleteriousness (blue=neutral, red=disease-causing). A score of 50 is recommended as a cut-off between neutral and disease-causing variants
Alamut© [58] Commercial software (Interactive Biosoftware)	Databases: RefSeq, dbSNP, Uniprot, InterPro, UCSC Genome Browser Database, PubMed, Ensembl. And Automated access to on-line prediction tools: PolyPhen2, SIFT, Align GVGD Access to splicing prediction tools (detailed in Section III.2.1.2.) “Alamut Batch” High-throughput annotation software for NGS analysis	Summarized report of the results of different prediction tools, according to their output format Designed for intensive variant analysis workflows

Table 5. Bioinformatics tools for the prediction of amino acid changes: websites, characteristics and output format [55-59]

A recent work has emphasised the importance of sequence alignments on the performance of prediction tools [60]. The authors constructed custom multiple sequence alignments called phenotype-optimized sequence ensembles (POSEs) that was tested on a training set of CFTR mutations.

A previous work already suggested that providing SIFT or PolyPhen-2 with custom alignments increased their performance relative to the default alignments employed by the algorithms [61]. This could explain that, if Alamut© is a highly interesting tool with its ease of use, some predictions obtained by using each tool separately with a custom algorithm could differ from Alamut© results (obtained with default alignments).

3.2.1.2. Prediction tools for the assessment of the impact on pre-mRNA splicing

Splicing mechanisms comprise exon recognition within large pre-mRNA molecules and the precise removal of flanking introns. Three elements constitute the core splicing signals: the intronic branch point, the acceptor site (or 3' splice site), including an inconstant upstream polypyrimidine tract (PPT), and the donor site (or 5' splice site). These core human splice site motifs contain only a part of the information that defines exons, whereas the rest corresponds to less conserved splicing regulatory elements. The latter are located within the exon or flanking introns, promoting or inhibiting exon recognition through exonic/intronic splicing enhancers (ESE or ISE) or silencers (ESS or ISS), respectively (Figure 3).




Figure 3. A schematic of key splicing motifs and regulatory elements. Adapted by Le Guédard-Méreuze S. from Wang and Burge, 2008 [62, 63].

Many bioinformatics tools have been developed to predict which splicing modification is the most probable for a given sequence variation — exon skipping, cryptic splice sites activation, use of *de novo* splice sites — or if the variant may be considered as neutral regarding its impact on splicing. Most algorithms were developed based on biostatistical and experimental analyses of information contained in the genomic sequence. They provide a score depending on the strength of the considered splice site. Indeed, the strength of splicing motifs is a key parameter to predict the impact of a sequence variation. Performance of these tools has been widely studied by comparing the results of predictions with experimental assays for various genes including *CFTR* [39, 63-66]. In 2012, Houdayer and collaborators performed a large-scale study of VUCS in *BRCA* genes in order to assess the performance of six prediction tools [67]. This work provided guidelines for the proper use of these tools and for the interpretation of prediction results.

Table 6 summarizes principle and main characteristics of the most 'popular' bioinformatics programs and ASSEDA, a recently developed program [68-73].

Method and Web site	Algorithm	Output
MaxEntScan [72]	Based on a Maximum Entropy Model (MEM): Modelling the sequences of short sequence motifs such as those involved in RNA splicing which simultaneously accounts for non-adjacent as well as adjacent dependencies between positions.	
Consensus splice sites		
	HSF (WMM): Quantification of the relative likelihood of candidate splice site sequence to show coincidence with consensus sequence	Numerical Score (0-100)
Human Splicing Finder (HSF) [73] Associates weight matrix model (WMM) and Maximum Entropy Model (MEM)	MaxEnt (MEM): Statistical approach representing the least biased approximation for the distribution of sequence motifs, from available data (real and decoy splice sites). Incorporates local adjacent and non-adjacent position dependencies	Numerical Score (0-10)
cis-regulatory elements		
	ESEfinder* RESCUE-ESE* Predicted PESE AND PESS Octamers from Zhang & Chasin *See Prediction tools for <i>cis</i> -regulatory elements	See Prediction tools for <i>cis</i> -regulatory elements
NNSplice [74]	Machine learning approach that recognizes sequence patterns once it is trained with sets of DNA sequences encompassing authentic and decoy splice sites. Based on a hidden Markov Model (HMM): Incorporates local adjacent position dependencies	Score between 0 and 1
Automated Splice Site and Exon Definition Analysis (ASSEDA) [75] <i>Restricted access: registration required</i>	Analyses splicing mutations according to changes in total exon information: information content of a spliced exon from the cumulative contributions of sequences recognized by the spliceosomal machinery and the distribution distances separating binding sites within the same exon.	ΔRi_{total} values (differences in probability of relative inclusion or exclusion of the wild type and mutated exon in mature mRNA)
Prediction tools for cis-regulatory elements		
ESEfinder [76]	Prediction of SR protein specific putative ESE, based on an in vitro SELEX approach dependent on addition of individual SR proteins	ESE motif score
RESCUE-ESE [77] (Relative enhancer and silencer classification by unanimous enrichment)	Statistical approach based upon different distribution of hexamers in exons and introns with different properties (e.g. weak and strong splice sites)	Z-score (Highlights extremely over- or under-represented hexamers)

Table 6. Main characteristics of several Splicing prediction tools [74-79]

It is important to note that consequences on splicing of exonic synonymous and non-synonymous *CFTR* variants must be assessed, as suggested by recent of experimental studies [39, 80].

3.2.2. Deep intronic variants

The examples of insertion of intronic sequences called pseudo-exons (or cryptic exons) in mature transcripts of various genes are becoming ever more numerous and their role in human diseases has been largely demonstrated. We saw in section 2.2 that NGS strategies currently allow scanning of *CFTR* deep intronic regions [18], resulting in a growing number of new identified deep intronic variants.

Bioinformatics tools described above, which assess the impact of variants on splicing, can also be used to evaluate deep intronic mutations. We tested these algorithms on mutations identified in CF patients after NGS sequencing of the entire *CFTR* locus and they showed satisfactory results [18]. Indeed, prediction tools allowed the selection of possible disease-causing mutations (i.e. predicted impact on splicing by inclusion of pseudo-exons) and predictions were confirmed by *in vitro* functional studies using minigene constructs (see section 3.3.1.1) and by direct analysis of aberrant transcripts from nasal epithelial cells of patients (see 3.3.2.1).

3.3. *In vitro/ex vivo* functional analyses

3.3.1. Cell lines transfection experiments

The type of cells used for transfection depends on the tissue that is studied and the clinical context. Pulmonary (BEAS-2B, A549, Calu-3) or intestinal/colic (CACO-2, T84) immortalized cells (by SV40 or carcinoma) contain an appropriate concentration of transcriptional and splicing factors for *CFTR* protein synthesis. Cells stably transfected with mutated *CFTR* can also be used (CFBe41o-, CFPAC-1). Stable expression is usually obtained by lentivirus transduction and transient transfection by chemical agent (Polyfect, interferin). In this case, the endogenous CF molecular and cellular context (inflammation) should also be considered.

3.3.1.1. Splicing assessment

Minigenes are autonomic cyclic entity containing promoter and exons and are produced by clonal amplification in bacteria [81, 82]. They contain a genomic segment from the gene of interest (here *CFTR*) that includes exon and flanking intronic regions (length can range from ten to thousands of nucleotides, an average of 300 bp) or only intronic regions in the case of evaluation of potential creation of a pseudo-exon. To determine whether a mutation is responsible for altered splicing, minigenes can also include *cis*-regulatory elements if affected (ESE, ESS, ISE or/and ISS) [83]. These regions of interest are framed by two invariable exons, which are part of the system. Every assay of transfection in cell lines compares the wild-type and mutated (through directed mutagenesis) constructs [84]. All *CFTR* exons are needed to produce a mature and functional protein. Thus, a modification of transcript in the *in vitro* system suggests that the assessed *CFTR* change has a deleterious effect on exon splicing. An

ever-increasing number of mini-gene studies have been performed to assess the pathogenicity of *CFTR* variants [39, 60, 80, 84]. This strategy, despite its limitations, is of high interest in the overall strategy for the characterization of rare sequence variations.

3.3.1.2. Expression vectors for the quantification of mRNA, protein or *CFTR*-specific chloride conductance

Full-length *CFTR* cDNA is classically inserted in expression vector system (e.g. pcDNA3 or p-Tracer) upon a promoter that may be drug-activated (G418, tetracycline or doxycycline-activation). To assess point variants or small indels, directed mutagenesis is carried out (usually QuikChange Mutagenesis kits®, Agilent Technologies). To assess molecular consequences of large rearrangements concerning one or more exons, a truncated *CFTR* cDNA can be inserted in the expression vector [85-87]. Transient or stable transfection can be performed in eukaryotic cells (describe in III.3.1. section). 3-HA tag (in the fourth loop of *CFTR*) can be introduced to easily visualize protein expression. Then, measurement of mRNA expression and evaluation of function and localization of the *CFTR* protein can be performed for each alternative transcript construct, compared to wild-type.

Automated real-time RT-PCR allows the relative straightforward quantification of mRNA transcripts with specific primers and appropriate reference genes for normalization. mRNA level informs about future protein quality and quantity.

Protein assessment consists in the implementation of complementary experiments for protein quantification, evaluation of its maturation or its cellular localization. Main techniques are detailed below. The effect of variants on *CFTR* expression and maturation is assessed based on the detection of immature (core-glycosylated, B band, ~150-kD) and/or mature (additional glycosylation in the Golgi, C band ~170-190 kDa) *CFTR* forms by immunoblotting. Long-term pulse-chase experiments can provide additional information on the lifetime of *CFTR* on cellular compartments [88]. Immunocytochemical assays (Immunofluorescence (IF) based) can highlight the cellular localization of the *CFTR* protein. However, most difficulties noted in IF experiments relate to non-specific antibody staining and the effect of sample processing on characteristics of cell development. Moreover, confusion between cell surface (where *CFTR* is active) and subsurface (where it would not) may occur. Therefore, more sensitive and specific antibodies as well as co-localization assays with other cell surface markers (such as β -tubulin or WGA) are needed. Finally, this remains a qualitative or semi-quantitative method.

CFTR function and activity, i.e. *CFTR*-specific chloride conductance, can be determined by patch-clamp electrophysiology, halide selective electrode technique, radioisotope efflux assays and by fluorescence-based halide efflux measurement. The use of a *CFTR*-activating appropriate drug (such as forskolin, isobutylmethylxanthine (IBMX), isoproterenol, terbutaline, genistein, adenosine, etc.) or ATP followed by specific *CFTR* inhibitor *CFTRinh-172* permits *CFTR*-dependant or independent chloride transport, respectively. To date, the easiest approach developed consists in Iodide efflux based on fluorescence measurement. YFP fluorescence is dependent on YFP expression levels and iodide concentration. Compared with conventional plate-bound *CFTR* functional assays, the flow cytometric approach can be used to study *CFTR* function in cell suspension. It may be further adjusted to study *CFTR* function

in heterologous cell populations using cell surface markers and selection of cells that display high CFTR function. Technical limitations include the need to perform this assay in specialized centres (using expensive imaging equipment).

All these methods offer the possibility to evaluate the functional consequences of molecular abnormalities on CFTR and finally improve the classification of variants.

3.3.2. *Ex vivo* CF patients' cells assays

3.3.2.1. Analyses on primary airway cells and tissues

Characterization of CFTR molecular defect can partially be performed directly after biopsies of tissues that show sufficient CFTR expression. Nasal or lung airway epitheliums are optimal. These tissues are accessible by minimally invasive interventions and display an endogenous expression of CFTR transcripts and protein. Moreover, nasal and bronchial epitheliums show the same cellular composition (ciliated, goblet, columnar and immune cells) although ratios differ slightly [89]. Since quantification and detection of aberrant splicing and quantification or localization of proteins are possible in human tissues, information that they bring is crucial to assess the effect of variants and to propose a functional classification. However, this approach has its limitations and requires other functional assays to perform large-scale genotype–phenotype correlation studies. In addition, especially for nasal tissue, the low quantity of cells collected (out of 500.000 cells per brushing) only allows 'one-shot' tests and hinders mechanistic assays. Moreover, highly variable CFTR expression in heterogeneous cell types, in healthy individuals and in p.Phe508del homozygous patients has been described, varying from 0 to 100% [90]. Other genetic (see below) or environmental parameters could also modify CFTR expression levels.

3.3.2.2. *Ex vivo* culture of primary airway cells

Culture of primary cells from CF patients can be performed with brushed nasal or bronchial cells after biopsies. Wild-type endogenous CFTR protein is expressed at the apical membrane of polarized cells. Therefore, *in vitro* monolayer culture seems no longer adapted. Obtaining polarized cells is promoted by air–liquid interface culture (ALI), proposed since the 2000s, by an *ex vivo* system of collagen-coated porous membrane on which cells are plated after a phase of monolayer amplification or directly after nasal brushing. Basal adherent cells differentiate in all airways epithelial cell types, which organize into a pseudo-stratified epithelium [91].

This model offers the opportunity to perform functional assays described above to determine CFTR dysfunction. Molecular defect induced by a specific mutation can be qualitatively determined if the cell donor is homozygous for this mutation.

Technical limitations such as bacterial or fungi contaminations or absence of adherence complicate culture of cells obtained from CF patients. Moreover, further studies are needed to determine if extrapolation is possible between observations in primary cells directly after

brushing and after several weeks in culture media, particularly for quantitative level assessment.

3.3.2.3. Intestinal current measurement (ICM)

ICM was developed as a research tool to assess CFTR function in the 1990s and has been used as a diagnostic test since the early 2000s [92, 93]. At least four superficial rectal biopsies per patient, obtained by suction, are needed and mounted on adequate tissue sliders. ICM consists in blocking epithelial sodium channels by amiloride and stimulates cAMP-mediated CFTR-dependent chloride transport in a chloride-free solution with forskolin or IBMX. Cholinergic chloride transport and histaminic reaction were also evaluated and the sum of the response $\Delta I_{sc}^{\text{forskolin/IBMX+carbachol+histamine}}$ appears to be the best parameter to evaluate CFTR function by ICM, but reference values and ranges have not been established. This combination of ionic responses discriminates patients with CF from healthy subjects but not CF patients with pancreatic insufficiency (PI) or sufficiency (PS). ICM can detect a loss of CFTR function above 80%, therefore CF carriers and CFTR-RD patients may not be identified by this method. Moreover, mild mutations could result in a false-negative ICM.

ICM is not altered by secondary damage on tissue and thus better reveals the primary CFTR dysfunction (compared with nasal potential difference, see below). A new functional CFTR assay using primary CF intestinal organoids derived from patients and cultured *in vitro* may offer new tools to screen for therapy [94].

Finally, setup and maintenance of dedicated equipment by experienced and trained staff limits its use.

3.3.3. In vivo biomarkers assays of CFTR function

Sweat chloride Test (ST) and Nasal potential difference (NPD) measurement are used as diagnostic tests for CF. In atypical clinical context these *in vivo* tests can give additional arguments to further explore the *CFTR* locus (cf. Figure 2 that describes the molecular diagnostics step-by-step strategy). Furthermore, they provide complementary information for the interpretation of *CFTR* variations.

ST higher than 60 mmol/L is the 'gold standard' and discriminates between healthy and typical CF. Sweat electrolytes are higher in the most severely affected and are lower in those with mild mutation, who have partial rescue of channel function [95-97]. There are two major advantages for the use of sweat test in the evaluation of the *CFTR* mutation severity: (i) stability of the measure throughout life and (ii) non-invasive way of measurement which maintains skin integrity. Indeed, sweat electrolytes levels reflect the primary defect on the CFTR protein and do not highlight secondary consequences of its absence or dysfunction on affected organs. Furthermore, a new means for assessing the secretory function of CFTR has been recently developed based on β -adrenergic-mediated sweating. This method provides a unique evaluation of the purely secretory function of CFTR *in vivo*. It has been shown to be more sensitive in individuals carrying mutations that commonly exhibit normal or borderline sweat chloride rates, such as c.3718-2477C>T (legacy name: 3849+10kbC>T) [98].

The transepithelial NPD measurement estimates the net ion conductance across the nasal airway epithelium and indirectly measure CFTR activity. Sodium conductance is determined after amiloride perfusion (Na⁺). NPD parameters discriminate CF and CFTR-RD phenotypes and a correlation between NPD and disease severity has been shown [99], although there is an overlap in subjects with mild phenotype [97]. However, other sources of phenotypic variability (modifiers genes or environment) and technical limitations (i.e. maintenance of dedicated equipment and trained personnel) contribute to the inconsistencies of NPD across genotype-phenotype correlation studies. CFTR expression and NPD response can also be modified if nasal epithelium is affected by rhinosinusitis, polyposis or exposure to smoking [100]. However, despite the difficulty of setting up this technique, NPD assessment could be used as a complementary step to support CFTR dysfunction in inconclusive clinical cases and then to confirm the deleterious effect of *CFTR* variants identified in these patients.

4. Conclusion

New issues are emerging from the use of NGS technology in CF molecular diagnosis. On one hand, NGS approaches offer new possibilities by multiplexing samples and provide a wider coverage of the *CFTR* locus including deep intronic regions. NGS assay design can also include additional modifiers genes [31]. On the other hand, molecular diagnoses in emergency contexts challenge the possibility of sample multiplexing, and the increased number of VUCS will require complex functional analyses. However, as tools described above are constantly improving, the knowledge about *CFTR* variations is rapidly expanding, allowing geneticists and clinicians to provide patients with high quality information and adequate genetic counselling. Finally, the functional characterization of *CFTR* variations will provide rationale for a personalised medicine strategy driven by patients' genotype in the very near future.

Acknowledgements

We acknowledge all members of the technical team for CF molecular diagnosis: Jean-Pierre Altieri, Fanny Verneau and Lise Larrieu. We also thank the coordination team of the *CFTR*-France genetic database: Corinne Bareil and Corinne Thèze and all the collaborating members of this project. We are also grateful to the French Network of laboratories specialized in molecular diagnosis of CF (GenMucoFrance). Finally, we thank the French Association against CF (Vaincre la Mucoviscidose) for its constant support.

Author details

Anne Bergougoux^{1*}, Magali Taulan-Cadars², Mireille Claustres² and Caroline Raynal¹

*Address all correspondence to: anne.bergougoux@inserm.fr

1 Laboratory of Molecular Genetics, Montpellier Hospital, France

2 Montpellier University, France

References

- [1] Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science*. 1989 Sep 8;245(4922):1066-73. Erratum in: *Science* 1989 Sep 29;245(4925):1437.
- [2] Casals T, Ramos MD, Giménez J, Larriba S, Nunes V, Estivill X. High heterogeneity for cystic fibrosis in Spanish families: 75 mutations account for 90% of chromosomes. *Hum Genet*. 1997 Dec;101(3):365-70.
- [3] Tsui LC. The spectrum of cystic fibrosis mutations. *Trends Genet*. 1992 Nov;8(11):392-8.
- [4] Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. *Cell*. 1993 Jul 2;73(7):1251-4. Review.
- [5] Quintana-Gallego E, Delgado-Pecellín I, Calero Acuña C. CFTR protein repair therapy in cystic fibrosis. *Arch Bronconeumol*. 2014 Apr;50(4):146-50. doi: 10.1016/j.arbres.2013.07.013. [Article in English, Spanish].
- [6] Castellani C, Cuppens H, Macek M Jr, Cassiman JJ, Kerem E, Durie P, Tullis E, As-sael BM, Bombieri C, Brown A, Casals T, Claustres M, Cutting GR, Dequeker E, Dodge J, Doull I, Farrell P, Ferec C, Girodon E, Johannesson M, Kerem B, Knowles M, Munck A, Pignatti PF, Radojkovic D, Rizzotti P, Schwarz M, Stuhmann M, Tzetis M, Zielenski J, Elborn JS. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. *J Cyst Fibros*. 2008 May;7(3):179-96. doi: 10.1016/j.jcf.2008.03.009. Review.
- [7] Dequeker E, Stuhmann M, Morris MA, Casals T, Castellani C, Claustres M, Cuppens H, des Georges M, Ferec C, Macek M, Pignatti PF, Scheffer H, Schwartz M, Witt M, Schwarz M, Girodon E. Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders--updated European recommendations. *Eur J Hum Genet*. 2009 Jan;17(1):51-65. doi: 10.1038/ejhg.2008.136.
- [8] World Health Organisation Report "The molecular genetic epidemiology of cystic fibrosis". Available on: http://www.who.int/genomics/publications/en/HGN_WB_04.02_report.pdf [Accessed: 2015-02-07]
- [9] Abeliovich D, Lavon IP, Lerer I, Cohen T, Springer C, Avital A, Cutting GR. Screening for five mutations detects 97% of cystic fibrosis (CF) chromosomes and predicts a

- carrier frequency of 1:29 in the Jewish Ashkenazi population. *Am J Hum Genet.* 1992 Nov;51(5):951-6.
- [10] Chillón M, Dörk T, Casals T, Giménez J, Fonknechten N, Will K, Ramos D, Nunes V, Estivill X. A novel donor splice site in intron 11 of the CFTR gene, created by mutation 1811+1.6kbA-->G, produces a new exon: high frequency in Spanish cystic fibrosis chromosomes and association with severe phenotype. *Am J Hum Genet.* 1995 Mar; 56(3):623-9.
- [11] Costantino L, Claut L, Paracchini V, Coviello DA, Colombo C, Porcaro L, Capasso P, Zanardelli M, Pizzamiglio G, Degiorgio D, Seia M. A novel donor splice site characterized by CFTR mRNA analysis induces a new pseudo-exon in CF patients. *J Cyst Fibros.* 2010 Dec;9(6):411-8. doi: 10.1016/j.jcf.2010.08.009.
- [12] Faà V, Incani F, Meloni A, Corda D, Masala M, Baffico AM, Seia M, Cao A, Rosatelli MC. Characterization of a disease-associated mutation affecting a putative splicing regulatory element in intron 6b of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. *J Biol Chem.* 2009 Oct 30;284(44):30024-31. doi: 10.1074/jbc.M109.032623. Epub 2009 Sep 15.
- [13] Bareil C, Guittard C, Altieri JP, Templin C, Claustres M, des Georges M. Comprehensive and rapid genotyping of mutations and haplotypes in congenital bilateral absence of the vas deferens and other cystic fibrosis transmembrane conductance regulator-related disorders. *J Mol Diagn.* 2007 Nov;9(5):582-8.
- [14] Costantino L, Rusconi D, Claut L, Colombo C, Novara F, Paracchini V, Porcaro L, Capasso P, Zuffardi O, Seia M. A wide methodological approach to identify a large duplication in CFTR gene in a CF patient uncharacterised by sequencing analysis. *J Cyst Fibros.* 2011 Dec;10(6):412-7. doi: 10.1016/j.jcf.2011.06.007.
- [15] Metzker ML. Sequencing technologies—the next generation *Nat Rev Genet.* 2010 Jan; 11:31-46.
- [16] Bodi K, Perera AG, Adams PS, Bintzler D, Dewar K, Grove DS, Kieleczawa J, Lyons RH, Neubert TA, Noll AC, Singh S, Steen R, Zianni M. Comparison of commercially available target enrichment methods for next-generation sequencing. *J Biomol Tech.* 2013 Jul;24(2):73-86. doi: 10.7171/jbt.13-2402-002.
- [17] Chilamakuri CS, Lorenz S, Madoui MA, Vodák D, Sun J, Hovig E, Myklebost O, Meza-Zepeda LA. Performance comparison of four exome capture systems for deep sequencing. *BMC Genomics.* 2014 Jun 9;15:449. doi: 10.1186/1471-2164-15-449.
- [18] Bonini J, Varilh J, Raynal C, Thèze C, Beyne E, Audrezet MP, Ferec C, Bienvenu T, Girodon E, Tuffery-Giraud S, Des Georges M, Claustres M, Taulan-Cadars M. Small-scale high-throughput sequencing-based identification of new therapeutic tools in cystic fibrosis. *Genet Med.* 2015 Jan 8. doi: 10.1038/gim.2014.194.

- [19] Tewhey R, et al. Microdroplet-based PCR enrichment for large-scale targeted sequencing. *Nature Biotech.* 2009;27:1025-31.
- [20] Guo Y, Long J, He J, Li CI, Cai Q, Shu XO, Zheng W, Li C. Exome sequencing generates high quality data in non-target regions. *BMC Genomics.* 2012 May 20;13:194. doi: 10.1186/1471-2164-13-194.
- [21] Li H, Handsaker B, Wysoker A, et al. The sequence alignment/map format and SAM-tools. *Bioinformatics.* 2009;25:2078-9.
- [22] McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The genome analysis toolkit: a Map-Reduce framework for analyzing next-generation DNA sequencing data. *Genome Res.* 2010;20:1297-1303.
- [23] Treangen TJ, Salzberg SL. Repetitive DNA and next-generation sequencing: computational challenges and solutions. *Nat Rev Genet.* 2011 Nov 29;13(1):36-46. doi: 10.1038/nrg3117.
- [24] 1000 Genomes Project Database. Available on: <http://www.1000genomes.org/> [Accessed: 2015-02-07]
- [25] NCBI Short Genetic Variations Database. Available on: <http://www.ncbi.nlm.nih.gov/gate2.inist.fr/projects/SNP/> [Accessed: 2015-02-07]
- [26] Abou Tayoun AN, Tunkey CD, Pugh TJ, Ross T, Shah M, Lee CC, Harkins TT, Wells WA, Tafe LJ, Amos CI, Tsongalis GJ. A comprehensive assay for CFTR mutational analysis using next-generation sequencing. *Clin Chem.* 2013 Oct;59(10):1481-8. doi: 10.1373/clinchem.2013.206466.
- [27] Trujillano D, Ramos MD, González J, Tornador C, Sotillo F, Escaramis G, Ossowski S, Armengol L, Casals T, Estivill X. Next generation diagnostics of cystic fibrosis and CFTR-related disorders by targeted multiplex high-coverage resequencing of CFTR. *J Med Genet.* 2013 Jul;50(7):455-62. doi: 10.1136/jmedgenet-2013-101602. Epub 2013 May 17.
- [28] Guo X, Pace RG, Stonebraker JR, Commander CW, Dang AT, Drumm ML, Harris A, Zou F, Swallow DM, Wright FA, O'Neal WK, Knowles MR. Mucin variable number tandem repeat polymorphisms and severity of cystic fibrosis lung disease: significant association with MUC5AC. *PLoS One.* 2011;6(10):e25452. doi: 10.1371/journal.pone.0025452. Epub 2011 Oct 6.
- [29] Guillot L, Beucher J, Tabary O, Le Rouzic P, Clement A, Corvol H. Lung disease modifier genes in cystic fibrosis. *Int J Biochem Cell Biol.* 2014 Jul;52:83-93. doi: 10.1016/j.biocel.2014.02.011.
- [30] Gisler FM, von Kanel T, Kraemer R, Schaller A, Gallati S. Identification of SNPs in the cystic fibrosis interactome influencing pulmonary progression in cystic fibrosis. *Eur J Hum Genet.* 2013 Apr;21(4):397-403. doi: 10.1038/ejhg.2012.181.

- [31] Cutting GR. Modifier genes in Mendelian disorders: the example of cystic fibrosis. *Ann N Y Acad Sci.* 2010 Dec;1214:57-69. doi: 10.1111/j.1749-6632.2010.05879.x. Review.
- [32] Claustres M, Guittard C, Bozon D, Chevalier F, Verlingue C, Ferec C, Girodon E, Cazeneuve C, Bienvenu T, Lalau G, Dumur V, Feldmann D, Bieth E, Blayau M, Clavel C, Creveaux I, Malinge MC, Monnier N, Malzac P, Mittre H, Chomel JC, Bonnefont JP, Iron A, Chery M, Georges MD. Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France. *Hum Mutat.* 2000;16(2):143-56.
- [33] Sharma H, Mavuduru RS, Singh SK, Prasad R. Heterogeneous spectrum of mutations in CFTR gene from Indian patients with congenital absence of the vas deferens and their association with cystic fibrosis genetic modifiers. *Mol Hum Reprod.* 2014 Sep; 20(9):827-35. doi: 10.1093/molehr/gau047.
- [34] Bergougnot A, Viart V, Miro J, Bommart S, Molinari N, des Georges M, Claustres M, Chiron R, Taulan-Cadars M. Should diffuse bronchiectasis still be considered a CFTR-related disorder? *J Cyst Fibros.* 2015 pii: S1569-1993(15)00054-5.
- [35] Ramos MD, Trujillano D, Olivar R, Sotillo F, Ossowski S, Manzanares J, Costa J, Gartner S, Oliva C, Quintana E, Gonzalez MI, Vazquez C, Estivill X, Casals T. Extensive sequence analysis of CFTR, SCNN1A, SCNN1B, SCNN1G and SERPINA1 suggests an oligogenic basis for cystic fibrosis-like phenotypes. *Clin Genet.* 2014 Jul;86(1):91-5. doi: 10.1111/cge.12234.32
- [36] Bakouh N, Bienvenu T, Thomas A, Ehrenfeld J, Liote H, Roussel D, Duquesnoy P, Farman N, Viel M, Cherif-Zahar B, Amselem S, Taam RA, Edelman A, Planelles G, Sermet-Gaudelus I. Characterization of SLC26A9 in patients with CF-like lung disease. *Hum Mutat.* 2013 Oct;34(10):1404-14. doi: 10.1002/humu.22382.
- [37] Li W, Soave D, Miller MR, Keenan K, Lin F, Gong J, Chiang T, Stephenson AL, Durie P, Rommens J, Sun L, Strug LJ. Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities. *Hum Genet.* 2014 Feb;133(2):151-61. doi: 10.1007/s00439-013-1363-7.
- [38] Practice guidelines for the Interpretation and Reporting of Unclassified Variants (UVs) in Clinical Molecular Genetics, 2007. Available on: <http://cmgsweb.shared.hosting.zen.co.uk/> [Accessed: 2015-02-07]
- [39] Raynal C, Baux D, Theze C, Bareil C, Taulan M, Roux AF, Claustres M, Tuffery-Giraud S, des Georges M. A classification model relative to splicing for variants of unknown clinical significance: application to the CFTR gene. *Hum Mutat.* 2013;34:774-874.
- [40] 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, Hurles ME, McVean GA. A map of human genome variation from population-scale sequencing. *Nature.* 2010 Oct 28;467(7319):1061-73. doi: 10.1038/nature09534. Erratum in: *Nature* 2011 May 26;473(7348):544.

- [41] NHLBI GO Exome Sequencing Project. Available on: <http://evs.gs.washington.edu/EVS/> [Accessed: 2015-02-07]
- [42] Claustres M, Horaitis O, Vanevski M, Cotton RG. Time for a unified system of mutation description and reporting: a review of locus-specific mutation databases. *Genome Res.* 2002;12:680-8.
- [43] Cotton RGH, Auerbach AD, Beckmann JS, Blumenfeld OO, Brookes AJ, Brown AE, et al. Recommendations for locus-specific databases and their curation. *Hum Mutat.* 2008;29(1):2-5.
- [44] Cystic Fibrosis Mutation Database (CFMDB). Available on: www.genet.sick-kids.on.ca/cftr/ [Accessed: 2015-02-07]
- [45] Clinical and Functional Translation of CFTR (CFTR2), US CF Foundation, Johns Hopkins University, The Hospital for Sick Children, John Hopkins, USA. Available on: <http://www.cftr2.org/> [Accessed: 2015-02-07]
- [46] Castellani C, CFTR2 Team. CFTR2: how will it help care? *Paediatr Respir Rev.* 2013 May;14(Suppl 1):2-5. doi: 10.1016/j.prrv.2013.01.006.
- [47] Sosnay PR, Siklosi KR, Van Goor F, Kaniecki K, Yu H, Sharma N, Ramalho AS, Amaral MD, Dorfman R, Zielenski J, Masica DL, Karchin R, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. *Nat Genet.* 2013;45:1160-7.
- [48] CFTR-France. Available on: <https://cftr.iurc.montp.inserm.fr/CFTR/> (Restricted access) [Accessed: 2015-02-07]
- [49] He L1, Aleksandrov AA, Serohijos AW, Hegedus T, Aleksandrov LA, Cui L, Dokholyan NV, Riordan JR. Multiple membrane-cytoplasmic domain contacts in the cystic fibrosis transmembrane conductance regulator (CFTR) mediate regulation of channel gating. *J Biol Chem.* 2008 Sep 26;283(39):26383-90. doi: 10.1074/jbc.M803894200.
- [50] Mornon JP, Lehn P, Callebaut I. Atomic model of human cystic fibrosis transmembrane conductance regulator: membrane-spanning domains and coupling interfaces. *Cell Mol Life Sci.* 2008 Aug;65(16):2594-612. doi: 10.1007/s00018-008-8249-1.
- [51] Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. *Nat Methods.* 2010 Apr;7(4):248-9. doi: 10.1038/nmeth0410-248.
- [52] Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. *Nucleic Acids Res.* 2003 Jul 1;31(13):3812-4.
- [53] Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D, Zharkikh A, Thomas A. Comprehensive statistical study of 452 BRCA1 missense sub-

- stitutions with classification of eight recurrent substitutions as neutral. *J Med Genet.* 2006;43(4):295-305.
- [54] Yates CM, Filippis I, Kelley LA, Sternberg MJ. SuSPect: enhanced prediction of single amino acid variant (SAV) phenotype using network features. *J Mol Biol.* 2014 Jul 15;426(14):2692-701. doi: 10.1016/j.jmb.2014.04.026.
- [55] PolyPhen 2. Available on: <http://genetics.bwh.harvard.edu/pph2/> [Accessed: 2015-02-08]
- [56] SIFT. Available on: http://sift.jcvi.org/www/SIFT_BLink_submit.html [Accessed: 2015-02-08]
- [57] Align GVGD. Available on: http://agvgd.iarc.fr/agvgd_input.php [Accessed: 2015-02-08]
- [58] SuSPect. Available on: www.sbg.bio.ic.ac.uk/suspect [Accessed: 2015-02-08]
- [59] Alamut©. <http://www.interactive-biosoftware.com/> (Commercial software, not available online)
- [60] Masica DL, Sosnay PR, Cutting GR, Karchin R. Phenotype-optimized sequence ensembles substantially improve prediction of disease-causing mutation in cystic fibrosis. *Hum Mutat.* 2012 Aug;33(8):1267-74. doi: 10.1002/humu.22110.
- [61] Hicks S, Wheeler DA, Plon SE, Kimmel M. Prediction of missense mutation functionality depends on both the algorithm and sequence alignment employed. *Hum Mutat.* 2011;32:661-8.
- [62] Le Guédard-Méreuze S. Mutations in splicing cis-regulatory elements: role in human genetic diseases [thesis in French]. Université Montpellier 1, 2009.
- [63] Spurdle AB, Couch FJ, Hogervorst FB, Radice P, Sinilnikova OM, IARC Unclassified Genetic Variants Working Group. Prediction and assessment of splicing alterations: implications for clinical testing. *Hum Mutat.* 2008 Nov;29(11):1304-13. doi: 10.1002/humu.20901.
- [64] Vreeswijk MP, Kraan JN, van der Klift HM, Vink GR, Cornelisse CJ, Wijnen JT, Bakker E, van Asperen CJ, Devilee P. Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs. *Hum Mutat.* 2009 Jan;30(1):107-14. doi: 10.1002/humu.20811.
- [65] Sharma N, Sosnay PR, Ramalho AS, Douville C, Franca A, Gottschalk LB, Park J, Lee M, Vecchio-Pagan B, Raraigh KS, Amaral MD, Karchin R, Cutting GR. Experimental assessment of splicing variants using expression minigenes and comparison with in silico predictions. *Hum Mutat.* 2014 Oct;35(10):1249-59. doi: 10.1002/humu.22624.
- [66] Houdayer C, Caux-Moncoutier V, Krieger S, Barrois M, Bonnet F, Bourdon V, Bronner M, Buisson M, Coulet F, Gaildrat P, Lefol C, Léone M, Mazoyer S, Muller D, Remenieras A, Révillion F, Rouleau E, Sokolowska J, Vert JP, Lidereau R, Soubrier F,

- Sobol H, Sevenet N, Bressac-de Paillerets B, Hardouin A, Tosi M, Sinilnikova OM, Stoppa-Lyonnet D. Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined *in silico/in vitro* studies on BRCA1 and BRCA2 variants. *Hum Mutat.* 2012 Aug;33(8):1228-38. doi: 10.1002/humu.22101.
- [67] Yeo G, Burge CB. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. *J Comput Biol.* 2004;11(2-3):377-94.
- [68] Desmet FO, Hamroun D, Lalande M, Collod-Bérout G, Claustres M, Bérout C. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. *Nucleic Acids Res.* 2009 May;37(9):e67. doi: 10.1093/nar/gkp215.
- [69] Shapiro MB, Senapathy P. RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. *Nucleic Acids Res.* 1987 Sep 11;15(17):7155-74.
- [70] Reese MG, Eeckman FH, Kulp D, Haussler D. Improved splice site detection in Genie. *J Comput Biol.* 1997 Fall;4(3):311-23.
- [71] Mucaki EJ, Shirley BC, Rogan PK. Prediction of mutant mRNA splice isoforms by information theory-based exon definition. *Hum Mutat.* 2013 Apr;34(4):557-65. doi: 10.1002/humu.22277.
- [72] Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. ESEfinder: a web resource to identify exonic splicing enhancers. *Nucleic Acids Res.* 2003;31:3568-71.
- [73] Fairbrother WG, Yeh RF, Sharp PA, Burge CB. Predictive identification of exonic splicing enhancers in human genes. *Science.* 2002;297:1007-13.
- [74] MaxEntScan. Available on: http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html [Accessed: 2015-02-08]
- [75] Human Splicing Finder, version 2.4.1. Available on: <http://www.umd.be/HSF/> [Accessed: 2015-02-08]
- [76] NNSplice. Available on: http://www.fruitfly.org/seq_tools/splice.html [Accessed: 2015-02-08]
- [77] Automated Splice Site and Exon Definition Analyses (ASSEDA). Available on: <http://splice.uwo.ca/> (Restricted access: registration required) [Accessed: 2015-02-08]
- [78] ESEfinder. Available on: <http://rulai.cshl.edu/tools/ESE/> [Accessed: 2015-02-08]
- [79] Relative enhancer and silencer classification by unanimous enrichment (RESCUE ESE). Available on: <http://genes.mit.edu/burgelab/rescue-ese/> [Accessed: 2015-02-08]
- [80] Aissat A, de Becdelievre A, Golmard L, Vasseur C, Costa C, Chaoui A, Martin N, Costes B, Goossens M, Girodon E, Fanen P, Hinzpeter A. Combined computational-experimental analyses of CFTR exon strength uncover predictability of exon-skipping level. *Hum Mutat.* 2013;34:873-81.

- [81] Burn TC, Connors TD, Klinger KW, Landes GM. Increased exon-trapping efficiency through modifications to the pSPL3 splicing vector. *Gene*. 1995;161(2):183-7.
- [82] Cooper TA. Use of minigene systems to dissect alternative splicing elements. *Methods*. 2005 Dec;37(4):331-40.
- [83] Singh G, Cooper TA. Minigene reporter for identification and analysis of cis elements and trans factors affecting pre-mRNA splicing. *Biotechniques*. 2006 Aug;41(2):177-81.
- [84] Goina E, Fernandez-Alanis E, Pagani F. Approaches to study CFTR pre-mRNA splicing defects. *Methods Mol Biol*. 2011;741:155-69. doi: 10.1007/978-1-61779-117-8_11.
- [85] Scott A, Petrykowska HM, Hefferon T, Gotea V, Elnitski L. Functional analysis of synonymous substitutions predicted to affect splicing of the CFTR gene. *J Cyst Fibros*. 2012 Dec;11(6):511-7. doi: 10.1016/j.jcf.2012.04.009.
- [86] Taulan M, Guittard C, Theze C, Claustres M, Georges MD, A novel double 312 deletion underscores the importance of characterizing end points of the CFTR large 313 rearrangements. *Eur J Hum Genet*. 2009;17(12):1683-87.
- [87] Taulan M, Viart V, Theze C, Guittard C, Altieri JP, Templin C, Mely L, Claustres M, des Georges M. Identification of a novel duplication CFTRdup2 and functional impact of large rearrangements identified in the CFTR gene. *Gene*. 2012 Jun 1;500(2):194-8. doi: 10.1016/j.gene.2012.03.043.
- [88] Aleksandrov AA, Kota P, Aleksandrov LA, He L, Jensen T, Cui L, Gentzsch M, Dokholyan NV, Riordan JR. Regulatory insertion removal restores maturation, stability and function of DeltaF508 CFTR. *J Mol Biol*. 2010 Aug 13;401(2):194-210. doi: 10.1016/j.jmb.2010.06.019.
- [89] Bergougnot A, Claustres M, de Sario A. Nasal epithelial cells, a tool to study DNA methylation in airway diseases. *Epigenomics*. 2015 Feb;7(1):119-26. doi: 10.2217/epi.14.65.
- [90] van Meegen MA, Terheggen-Lagro SW, Koymans KJ, van der Ent CK, Beekman JM. Apical CFTR expression in human nasal epithelium correlates with lung disease in cystic fibrosis. *PLoS One*. 2013;8(3):e57617. doi: 10.1371/journal.pone.0057617.
- [91] Hajj R, Baranek T, Le Naour R, Lesimple P, Puchelle E, Coraux C. Basal cells of the human adult airway surface epithelium retain transit-amplifying cell properties. *Stem Cells*. 2007 Jan;25(1):139-48.
- [92] Hirtz S, Gonska T, Seydewitz HH, Thomas J, Greiner P, Kuehr J, Brandis M, Eichler I, Rocha H, Lopes AI, Barreto C, Ramalho A, Amaral MD, Kunzelmann K, Mall M. CFTR Cl⁻ channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. *Gastroenterology*. 2004 Oct;127(4):1085-95.

- [93] De Jonge HR, Ballmann M, Veeze H, Bronsveld I, Stanke F, Tümmler B, Sinaasappel M. Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers. *J Cyst Fibros*. 2004 Aug;3 Suppl 2:159-63.
- [94] Dekkers JF, Wiegerinck CL, de Jonge HR, Bronsveld I, Janssens HM, de Winter-de Groot KM, Brandsma AM, de Jong NW, Bijvelds MJ, Scholte BJ, Nieuwenhuis EE, van den Brink S, Clevers H, van der Ent CK, Middendorp S, Beekman JM. A functional CFTR assay using primary cystic fibrosis intestinal organoids. *Nat Med*. 2013 Jul;19(7):939-45. doi: 10.1038/nm.3201.
- [95] Farrell PM, Kosciak RE. Sweat chloride concentrations in infants homozygous or heterozygous for F508 cystic fibrosis. *Pediatrics*. 1996 Apr;97(4):524-8.
- [96] Davis PB, Schluchter MD, Konstan MW. Relation of sweat chloride concentration to severity of lung disease in cystic fibrosis. *Pediatr Pulmonol*. 2004 Sep;38(3):204-9.
- [97] Wilschanski M, Dupuis A, Ellis L, Jarvi K, Zielenski J, Tullis E, Martin S, Corey M, Tsui LC, Durie P. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. *Am J Respir Crit Care Med*. 2006 Oct 1;174(7):787-94. Epub 2006 Jul 13.
- [98] Quinton P, Molyneux L, Ip W, Dupuis A, Avolio J, Tullis E, Conrad D, Shamsuddin AK, Durie P, Gonska T. β -adrenergic sweat secretion as a diagnostic test for cystic fibrosis. *Am J Respir Crit Care Med*. 2012 Oct 15;186(8):732-9. doi: 10.1164/rccm.201205-0922OC.
- [99] Ho LP, Samways JM, Porteous DJ, Dorin JR, Carothers A, Greening AP, Innes JA. Correlation between nasal potential difference measurements, genotype and clinical condition in patients with cystic fibrosis. *Eur Respir J*. 1997 Sep;10(9):2018-22.
- [100] Bagheri-Hanson A, Nedwed S, Rueckes-Nilges C, Naehrlich L. Intestinal current measurement versus nasal potential difference measurements for diagnosis of cystic fibrosis: a case-control study. *BMC Pulm Med*. 2014 Oct 4;14:156. doi: 10.1186/1471-2466-14-156.

IntechOpen

